PLLA Collagen Biostimulators: How Safe Are They — and How Satisfied Are Patients?

Evidence-Based Collagen Biostimulation: A Deep Dive Into a 52-Patient Prospective Study

Study in One Sentence

A single facial treatment with a PLLA collagen biostimulator was generally well tolerated in this 52-patient prospective cohort, with mostly short-lived local reactions, one small painless clinical nodulation that resolved without treatment, and stable patient-rated aesthetic improvement through Day 150.

Why PLLA Is Different From a Conventional Dermal Filler

Facial rejuvenation has moved increasingly toward minimally invasive treatments that aim to create natural-looking changes with limited downtime. Within this shift, collagen biostimulators have become particularly relevant because they are designed to stimulate tissue remodeling rather than simply provide immediate filling volume.

Poly-L-lactic acid, or PLLA, is a biocompatible synthetic polymer with established biomedical applications. In aesthetic medicine, it is injected as a suspension and works gradually by stimulating collagen production. The clinical goal is therefore different from that of a conventional hyaluronic-acid filler: instead of relying mainly on immediate gel volume, PLLA is intended to create a progressive improvement in tissue support, skin quality, and facial volume over time.

That gradual mechanism is also why patient counseling matters. The treatment is not designed to create an instant dramatic transformation. Patients need to understand that the visible result evolves over time and that satisfaction depends not only on the final cosmetic outcome, but also on the recovery experience — discomfort, bruising, swelling, and expectations during the weeks after treatment.

What This Prospective Study Wanted to Answer

Most previous safety and satisfaction data on PLLA had come from retrospective research. Bravo and colleagues therefore designed a prospective investigation to evaluate both sides of the treatment experience: the clinical safety profile and the patient's own assessment of aesthetic improvement.

The study was conducted at a single private clinic in Rio de Janeiro between August 2023 and August 2024. Patients were followed clinically for 150 days, while a patient diary captured early adverse effects during the first 30 days. Aesthetic satisfaction was assessed with the Global Aesthetic Improvement Scale (GAIS) at Days 90 and 150.

Injection Sites Used in the Study

• Zygomatic region: an entry point defined using the tragus-to-subnasale horizontal line and the lateral orbital rim.
• Pre-masseteric region: a lower facial entry point immediately above the mandibular body at the anterior border of the masseter muscle.

How Was Satisfaction Measured?

Patient satisfaction was assessed with the Global Aesthetic Improvement Scale, a five-point rating system that compares overall appearance with baseline. In this study, a score of 1 represented exceptional improvement, 2 very improved, 3 improved, 4 unaltered, and 5 worsened.

GAIS was recorded on Day 90 and again on Day 150. Because the treatment targeted the zygomatic and pre-masseteric regions, the rating reflected overall improvement of the mid and lower face rather than a single isolated facial feature.

The Main Result: Patient-Rated Improvement Was Stable

All 52 patients completed the GAIS assessment at both study time points. At Day 90, the mean GAIS was 2.32 ± 1.0. At Day 150, the mean was again 2.32, with a standard deviation of 0.8.

The difference between Day 90 and Day 150 was not statistically significant (p = 0.862). In practical terms, patient-rated aesthetic improvement remained stable during this part of follow-up rather than showing a clear decline between approximately three and five months.

What Did Patients Actually Feel During Recovery?

The early recovery data came from patient diaries covering the first 30 days. Importantly, only 36 of the 52 patients — 69.2% — completed the diary. Percentages below therefore refer to those 36 diary completers, not the full study population.

The overall pattern was consistent: local reactions were common when patients were specifically asked to record them, but they were usually mild to moderate and short-lived.

What Did the Clinicians Find?

Every patient underwent clinical examination on Days 0, 30, 60, 90, 120, and 150, including facial palpation and assessment for adverse events.

Only one notable clinical adverse event was identified: at Day 60, a small 4-mm, painless, non-visible nodulation was palpated in the right pre-zygomatic region. It resolved completely by Day 90 without intervention.

Three patients also reported minimally palpable lumps during the first few days after treatment. All disappeared within one week.

Recovery Experience Can Influence Satisfaction

One of the most interesting parts of the study was the relationship between recovery symptoms and later satisfaction. Longer duration of mild pain was inversely correlated with GAIS, with rs = -0.546 and p = 0.035. Longer duration of mild bruising also showed an inverse relationship with GAIS, with rs = -0.598 and p = 0.019.

Because lower GAIS values represent better aesthetic improvement, these correlations need to be interpreted carefully. The study discussion emphasized a broader clinical message: even mild post-procedure discomfort can influence the patient's overall perception of treatment success.

The duration of moderate pain also showed a statistically significant association with age (rs = -0.894, p = 0.041). The authors discussed the possibility that age-related differences in skin, subcutaneous tissue, and pain perception could affect the recovery experience, although this finding came from a small subgroup and should not be overgeneralized.

So, Is PLLA "Safe"?

Within this prospective cohort and this specific treatment protocol, the authors concluded that the PLLA product was safe and well tolerated. Most reported effects were temporary local reactions, and no major clinical adverse event requiring treatment was observed during the 150-day follow-up.

That conclusion should be kept within the boundaries of the study. Safety here means that in 52 selected female patients treated by an experienced dermatologist under a standardized protocol, short-term and mid-term follow-up showed mostly mild transient reactions and one self-resolving nodulation.

It does not prove that every PLLA product, injector, dilution, anatomical area, patient, or treatment plan has the same risk profile. The study itself notes that nodules, edema, bacterial infection, and rare major complications have been reported in the wider PLLA literature.

Who Was This Treatment Intended to Help?

The study conclusion described PLLA as an effective non-surgical option for patients with mild to moderate facial sagging. The treatment targeted the mid and lower face rather than a single wrinkle or isolated volume deficit.

The underlying aesthetic logic is gradual collagen stimulation. This makes the treatment concept particularly relevant when the goal is progressive tissue support and improvement in facial laxity rather than an immediate dramatic change.

What Patients Should Understand Before Facial PLLA

The article repeatedly emphasizes realistic expectations and individualized planning. PLLA results evolve gradually, and the recovery experience may include pain, bruising, swelling, redness, temporary hardening, small lumps, or transient discoloration.

Open communication is especially important because the treatment journey itself affects satisfaction. Patients should understand the expected timeline, the possibility of temporary injection-site reactions, the importance of follow-up, and the fact that the final outcome cannot be judged immediately after injection.

The study also reinforces that patient selection and technique matter. Its protocol excluded several groups that could have altered safety or outcome assessment, and all injections were performed by one experienced dermatologist.

• Expect gradual, not instant, biostimulation.
• Expect temporary injection-site symptoms to be possible.
• Do not judge the final result from the first few days after treatment.
• Follow the aftercare instructions specific to the product and injector.
• Attend scheduled reviews, especially if a lump, persistent swelling, pain, or other unexpected change develops.

Frequently Asked Questions